CVS/pharmacy commences new ‘Double My Bucks!’ promotion
WOONSOCKET, R.I. CVS/pharmacy has unveiled a special promotion that offers Extra Bucks rewards to customers purchasing prescriptions between May 1 and June 15.
Through the “Double My Bucks!” promotion, shoppers simply present a “Double My Bucks!” certificate along with their ExtraCare card to receive $2 Extra Bucks for every two prescriptions filled.
The certificates are available at the pharmacy counter at any CVS/pharmacy location and online at CVS.com. In addition, the “Double My Bucks!” certificates are included in the weekly store circulars throughout the month of May.
“Last year, CVS/pharmacy customers earned nearly $95 million in Extra Bucks savings from their prescription purchases,” stated John Barron, director of relationship marketing at CVS/pharmacy. “Reducing healthcare costs is a priority for most Americans and CVS/pharmacy remains committed to helping our customers do just that. In fact, CVS/pharmacy is the only pharmacy that pays customers back for purchasing prescriptions. We’re excited to offer ‘Double My Bucks!’ to help our customers save even more money on health care and thank them for choosing CVS/pharmacy as their pharmacy.”
FDA, SAMHSA to develop education campaign for methadone
ROCKVILLE, Md. A drug used to treat pain and heroin addiction is one of the most-abused prescription drugs in the country, but two government agencies will collaborate to educate the public on how to use it safety.
The Food and Drug Administration and the Substance Abuse and Mental Health Services Administration announced Monday that they would launch a joint education campaign within SAMHSA about the safe use of methadone.
The agencies will hold a press conference Tuesday morning to mark the launch of the program.
Decision Resources releases bipolar depression report
WALTHAM, Mass. Psychiatrists treating patients with bipolar depression base their prescribing decisions on a therapy’s effect on decrease in severity of depressive symptoms, a report released Monday has found.
Decision Resources’ report, “Bipolar Depression: Despite Negative Results, Physicians Still Hopeful About Aripiprazole,” based on a survey of psychiatrists in the United States and Europe, also found that an orally administered drug that carries a lower risk of weight gain than AstraZeneca’s Seroquel (quetiapine fumarate) would earn a 21% patient share in bipolar depression in the United States and a 30% share in Europe.
Most of the people interviewed also thought that Abilify (aripiprazole), made by Bristol-Myers Squibb and Otsuka Pharmaceutical, is an efficacious therapy for bipolar depression despite its failure in clinical trials of people with the disorder.